United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,136 shares of the biotechnology company's stock after buying an additional 1,870 shares during the quarter. Erste Asset Management GmbH owned approximately 0.11% of United Therapeutics worth $16,957,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Great Lakes Advisors LLC raised its position in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after acquiring an additional 33 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock worth $1,761,000 after acquiring an additional 39 shares in the last quarter. MBM Wealth Consultants LLC raised its position in shares of United Therapeutics by 1.9% in the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company's stock worth $775,000 after acquiring an additional 41 shares in the last quarter. Finally, UMB Bank n.a. raised its position in shares of United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after acquiring an additional 51 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the company's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,464 shares of company stock valued at $42,396,244. 11.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on UTHR. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Stock Up 0.6 %

Shares of UTHR traded up $1.85 during mid-day trading on Friday, reaching $307.24. The company had a trading volume of 494,807 shares, compared to its average volume of 445,927. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a market capitalization of $13.80 billion, a P/E ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64. The stock has a 50 day moving average of $349.77 and a two-hundred day moving average of $358.48.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the business earned $4.36 earnings per share. On average, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.